|Videos|July 4, 2021
Dr. Ramasamy discusses investigational oral testosterone treatment
Author(s)Urology Times staff
Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.
Advertisement
In this video, Ranjith Ramasamy, MD, discusses SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule for which the FDA recently accepted a new drug application. Ramasamy is an associate professor of urology and director of male reproductive medicine and surgery at the University of Miami Miller School of Medicine.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA provides guidance on development pathway for testosterone therapy for women
2
Pearls & Perspectives: Leadership and Prostate Cancer, with Mark L. Gonzalgo, MD, PhD, MBA
3
Pedro Freitas, MD, on consolidative surgery vs prolonged systemic therapy in MIBC
4
Treatment Selection in Advanced Prostate Cancer
5